The aim of this meta-analysis was to evaluate the comparative effect of ADCs and other anti-HER2 therapy on progression-free survival (PFS) and overall survival (OS) for treatment of HER2-positive locally advanced or metastatic BC.<h4>Methods</h4>Relevant randomized controlled trials (RCTs) were retrieved from five databases. Here, ERBB2 is linked to breast cancer.